bs_bs_banner
Clinical and Experimental Immunology
O R I G I N A L A RT I C L E
doi:10.1111/cei.12308
Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients
E.-M. Reitter,* C. Ay,* A. Kaider,† R. Pirker,‡ C. Zielinski,‡ G. Zlabinger§ and I. Pabinger* *Clinical Division of Hematology and Hemostaseology, §Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center, †Section for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, and ‡Center of Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria
Accepted for publication 24 February 2014 Correspondence: I. Pabinger, Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria. E-mail: [email protected]
Summary Cytokines have been found to be elevated in cancer patients and have been associated with worse prognosis in single tumour entities. We investigated the association of eight different cytokines with venous thromboembolism (VTE) and prognosis in cancer patients. The Vienna Cancer and Thrombosis Study (CATS), a prospective study, includes patients with newly diagnosed tumour or disease progression. Patients with an overt infection are excluded. Study end-points are VTE, death, loss to follow-up or study completion. Interleukin (IL) serum levels were measured using the xMAP technology developed by Luminex. Among 726 included patients, no associations between IL levels and VTE were found, with the exception of a trend for IL-1β and IL-6 in pancreatic cancer. Elevated levels of IL-6 [as continuous variable per double increase hazard ratio (HR) = 1·07, 95% confidence interval (CI) = 1·027–1·114, P = 0·001, IL-8 (HR = 1·12, 95% CI = 1·062–1·170, P < 0·001) and IL-11 (HR = 1·37, 95% CI = 1·103–1·709, P = 0·005] were associated with worse survival. In subgroup analyses based on tumour type, colon carcinoma patients, who had higher IL-6 levels, showed a shorter survival (HR = 2·405, 95% CI = 1·252–4·618, P = 0·008). A significant association of elevated IL-10 levels with a decrease in survival (HR = 1·824, 95% CI = 1·098–3·031, P = 0·020) was seen among patients with lung cancer. No correlation between VTE and IL levels was found, but higher IL-6, IL-8 and IL-11 levels were associated with worse survival in cancer patients. Further, elevated IL-6 levels might be a prognostic marker in colorectal cancer and elevated IL-10 levels in lung cancer patients. Keywords: cancer, interleukin levels, survival, thrombosis
Introduction Cancer is associated with the occurrence of venous thromboembolism (VTE) [1], which affects up to 20% of all cancer patients [2–4]. However, the rate may even be underestimated because of asymptomatic VTE. The incidence of VTE differs widely between the various tumour types [1,5,6], with the highest risk of VTE observed in patients suffering from pancreatic, stomach, lung or colorectal cancer, as well as in patients with brain tumours [6–9]. The occurrence of VTE negatively affects the prognosis of cancer patients and is among the most important causes of death in these patients [10–12]. Many risk factors related to patient characteristics, tumour types and treatment influence the development of VTE in cancer patients [6]. A
number of biomarkers of haemostasis and inflammatory markers have been found to play the role of risk factors of VTE in patients with cancer [13–16]. There is evidence that elevated levels of interleukins (ILs) could be associated with VTE [17–19]. Various ILs are elevated in cancer patients, dependent upon type and stage of the tumours [20,21]. In particular, IL-6 and IL-8 play an important role in the process of inflammation and, therefore, also in the development and progression of cancer. IL-6 induces both T-lymphocyte proliferation and angiogenesis, which then influence growth, differentiation and migration of tumour cells. IL-8 is involved in stimulating neutrophils and angiogenesis [22]. IL-10, which acts as an immunoinhibitory cytokine, is often elevated in patients with lung cancer, whereas in patients with colorectal cancer
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
253
E.-M. Reitter et al.
the levels of IL-6 are increased [19,21,23–25]. Elevated levels of circulating IL-6 and IL-8 are often associated with poor survival rates, especially in patients suffering from lung cancer [24,26–30]. The macrophage inflammatory protein-1α [CCL-3 (chemokine ligand 3)] is involved in acute inflammation via recruiting and activating leucocytes [31]. In the present study, we evaluated the associations between different ILs and the occurrence of VTE as well as overall survival in patients with cancer.
Materials and methods Patients
day of study entry. All blood samples were collected at the same time of day, in the morning (9 a.m.–12 p.m.). The serum blood was then centrifuged at 3600 g for 10 min using the Rotanta/TRC centrifuge (Hettich, Tuttlingen, Germany). Serum aliquots were stored at −80°C until measurements were conducted in series. The samples of each individual patient were coded prior to laboratory analysis. Assessment of cytokine serum levels was performed using the xMAP technology developed by Luminex (Riverside, CA, USA). This is a bead-based system for multiplex testing of cytokines, chemokines and growth factors. Specific anticytokine antibodies as well as recombinant cytokines were obtained from R&D Systems (Minneapolis, MN, USA). Measurements were performed using a Luminex analyser.
Statistical analysis
This study included patients with cancer who were recruited into the Vienna Cancer and Thrombosis Study (CATS), an ongoing prospective and observational cohort study initiated in October 2003. The details of the study have been described previously [15,19]. The study was approved by the ethics committee of the Medical University of Vienna. Each patient gave his/her written informed consent. CATS enrolled patients with cancer of the breast, lung, upper or lower gastrointestinal tract, pancreas, kidney, prostate or other sites and patients with haematological malignancies. Patients were divided into newly diagnosed cancer patients versus those with disease progression after complete or partial remission, and were observed for a period of up to 2 years. Patients with an overt bacterial or viral infection within the last 2 weeks or who had undergone surgery or radiotherapy within the last 2 weeks, as well as patients who had had chemotherapy or a venous or arterial thromboembolism within the last 3 months, were excluded from study entry. Patients treated with vitamin K antagonists or low-molecular-weight heparin (LMWH) for long-term anti-coagulation were also excluded. However, thromboprophylaxis while being hospitalized was not an exclusion criterion. At the time of inclusion, data on medical history, type and stage of tumour were collected. During the observation period, patients were contacted by postal mail or telephone approximately every 3 months in order to collect data on the clinical course of their disease, in particular concerning the occurrence of VTE and anticancer treatment. Study end-points were the occurrence of VTE (which had to be confirmed objectively by means of duplex sonography, phlebography, computerized tomography or ventilation– perfusion lung scan), death due to any cause, loss to follow-up or completion of the 2-year study period.
Continuous variables are described by the mean ± standard deviation or the median and the 25th–75th percentiles in case of non-normally distributed continuous data. Categorical variables are described by absolute numbers and percentages. The median follow-up time was calculated using the reverse Kaplan–Meier method. Survival probabilities were estimated by the Kaplan–Meier method. Spearman’s correlation coefficient was used to describe the degree of correlation between the investigated IL serum levels. Univariate and multivariable Cox regression analyses were used to evaluate the effect of the IL serum levels on the development of VTE and on survival. With respect to the outcome of VTE, the observation end-point was fatal or non-fatal VTE. Data were censored at death, end of observation period after 2 years or loss to follow-up. Considering the end-point death, data were censored at the end of the observational period after 2 years or loss to follow-up. Due to the large number of patients with IL serum levels equal to zero, each of the investigated IL parameters was represented by two prognostic factors within the Cox regression models: first, a binary variable discriminating between patients with IL serum levels equal to zero or greater than zero, and secondly a continuous variable comprising the log2-transformed IL serum level of patients with IL serum levels greater than zero. The log2-transformation was used to normalize the skewed distribution of IL serum levels greater than zero. The value of the continuous variable was set to zero in the case of patients with zero IL serum levels. Two-sided P-values smaller than 0·05 were considered to indicate statistical significance. All analyses were performed with sas version 9·3.
Laboratory analysis
Study population
Venous blood samples were drawn by atraumatic and sterile vein puncture into vacuum tubes with serum clot activator (Vacuette, Greiner-Bio One, Kremsmuenster, Austria) on the
Overall, 726 cancer patients with a median age of 62·0 years were included between October 2003 and March 2009. Patient characteristics are listed in Table 1.
254
Results
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
ILs – predictors for survival in cancer Table 1. Patient characteristics (n = 726).
Outcome VTE
Age at study entry, median (min.; max.), years BMI, mean ± s.d., kg/m2 Gender Male Female Type of cancer Brain Breast Colon Kidney Lung Lymphoma Multiple myeloma Pancreas Prostate Stomach Others Treatment before study inclusion (ie. CHT, RT or surgery)
62·0 (18; 88) 25·3 ± 4·5 n (%) 382 (52·6) 344 (47·4) n (%) 77 (10·6) 129 (17·8) 98 (13·5) 22 (3·0) 109 (15·0) 70 (9·6) 15 (2·1) 47 (6·5) 75 (10·3) 37 (5·1) 47 (6·5) 311 (42·8)
BMI = body mass index; CHT = chemotherapy; RT = radiotherapy; s.d. = standard deviation.
The tumour types consist of malignancies of the breast (n = 129), brain (n = 77), lung (n = 109), stomach (n = 37), colon (n = 98), pancreas (n = 47), kidney (n = 22), prostate (n = 75), multiple myeloma (n = 15) and lymphoma (n = 70). Other tumour entities, such as malignancies of the gynaecological system, sarcoma, cholangiocellular carcinoma and urothelial carcinoma, are combined in the ‘others’ group (n = 47). Among solid tumours, localized tumours were found in 263 patients, whereas distant metastasis was present in 301 patients. There were 539 newly diagnosed patients, and 187 patients had suffered from disease progression following a complete or partial remission. The median follow-up time of the patients was 705 days (25th–75th percentiles: 262– 731 days).
During the study period, 52 patients (7·2%) developed a VTE. Of these patients, 25 (48·1%) had a deep vein thrombosis (DVT), 19 (36·5%) a pulmonary embolism (PE), one of which had a fatal PE, two a combined DVT and PE (3·8%) and six (11·5%) other kinds of VTE (portal vein thrombosis, sinus vein thrombosis, brachial vein thrombosis, inferior vena cava thrombosis, jugular vein thrombosis). In the total study population, none of the investigated cytokine levels (i.e. IL-1β, IL-3, IL-4, IL-6, IL-8, IL-10, IL-11, CCL-3) showed an association with the occurrence of VTE (see Table 2). Separate analyses were performed regarding the different tumour entities. In these analyses, only tumour entities with a VTE rate of more than 5% (i.e. cancer of the brain, colon, lung, pancreas and stomach) were considered. Evaluating the effects of the binary prognostic factors (levels below versus levels above detection limit) only in patients with pancreatic cancer, IL-1β [hazard ratio (HR) = 7·16, 95% confidence interval (CI) = 1·906–30·895, P = 0·004) and IL-6 (H = 13·23, 95% CI = 1·656–1711·29, P = 0·01] were associated with an increased risk for VTE.
Outcome survival Overall, 337 patients (46·4%) died within the study period. In univariate analyses, no correlation was found between the levels of IL-1β, IL-3, IL-4, IL-10 and CCL-3 and survival (see Table 2). Both a twofold increase of IL-6 levels (HR per double increase = 1·07, 95% CI = 1·027–1·114, P = 0·001) and IL-8 levels (HR per double increase: 1·12, 95% CI = 1·062–1·170, P < 0·001) were associated with poor survival. IL-11 levels above zero also correlated negatively with the patients’ survival (HR per double increase = 1·37, 95% CI = 1·103– 1·709, P = 0·005). However, among the group of patients
Table 2. Cytokine levels in univariate Cox regression analyses in the study population. VTE Parameter
HR
Age* Gender† M-stage‡ IL-1β§ IL-3§ IL-4§ IL-6§ IL-8§ IL-10§ IL-11§ CCL-3§
0·99 0·86 2·50 0·98 0·99 1·11 1·08 1·06 1·01 0·90 0·99
Survival
95% CI 0·97 0·50 1·22 0·80 0·84 0·86 0·98 0·94 0·83 0·76 0·90
1·01 1·49 5·09 1·20 1·18 1·42 1·20 1·20 1·22 1·06 1·10
P-value
HR
0·323 0·587 0·012 0·792 0·549 0·708 0·118 0·210 0·302 0·349 0·726
1·01 0·78 5·09 1·02 1·03 0·10 1·07 1·12 1·05 0·97 0·98
95% CI 1·00 0·63 3·81 0·94 0·96 0·90 1·03 1·06 0·97 0·91 0·94
P-value 1·02 0·97 6·80 1·11 1·10 1·11 1·11 1·17 1·14 1·04 1·02
0·004 0·027 < 0·001 0·5885 0·4495 0·9765 < 0·0015 < 0·0015 0·1585 0·0115 0·6045
P-value for the combination of the binary and continuous variable. *Per year of life; †female versus male; ‡for solid tumours only; §hazard ratio (HR) per double increase of the continuous interleukin (IL) serum levels. CCL-3 = chemokine ligand 3; VTE = venous thromboembolism; CI = confidence interval. 5
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
255
E.-M. Reitter et al. Table 3. Interleukin (IL) levels and survival in the study population: multivariable Cox regression analyses, including cytokine levels, age and gender-adjusted. Parameter
HR
Age* Gender† IL-1β‡ IL-3‡ IL-4‡ IL-6‡ IL-8‡ IL-10‡ IL-11‡ CCL-3‡
1·01 0·85 0·93 0·95 0·95 1·15 1·12 1·07 0·94 0·93
95% CI 0·997 0·680 0·838 0·879 0·825 1·089 1·051 0·952 0·865 0·890
P-value 1·015 1·061 1·040 1·032 1·089 1·211 1·182 1·194 1·014 0·977
0·210 0·151 0·0204 0·4704 0·6924 < 0·0014 < 0·0014 0·5214 0·0124 0·0044
4
P-value for the combination of the binary and continuous variable. *Per year of life; †female versus male; ‡hazard ratio (HR) per double increase of the continuous IL serum levels. CI = confidence interval; CCL-3 = chemokine ligand 3.
with IL-11 levels above zero, the extent of the IL-11 level seemed to have no further influence on survival (HR per double increase = 0·97, 95% CI = 0·908–1·037, P = 0·376). In multivariable analyses, after adjustment for age and gender, the association of the levels of IL-1β (HR per double increase = 0·93, 95% CI = 0·838–1·040, P = 0·020), IL-6 (HR per double increase = 1·15, 95% CI, 1·089–1·211, P < 0·001), IL-8 (HR per double increase = 1·12, 95% CI = 1·051 −1·182, P < 0·001) and IL-11 (HR per double increase = 0·94, 95% CI = 0·865–1·014, P = 0·012) with risk of mortality remained statistically significant. Patients with increased CCL-3 levels showed a better survival outcome (HR per double increase = 0·93, 95% CI = 0·89–0·977, P = 0·004). For detailed results see Table 3. Furthermore, we performed multivariable analyses with adjustment for age, gender and tumour stage (localized tumour versus distant metastasis) by including only the solid tumours. For these analyses, we excluded patients with brain tumours as well as patients with multiple myeloma and lymphoma. From the remaining patients (n = 564), 276 (48·9%) died within the follow-up period (55% male). In these patients, IL-6 (HR per double increase = 1·173, 95% CI = 1·100–1·251, P < 0·001) and IL-8 (HR per double increase = 1·092, 95% CI = 1·023–1·166, P = 0·008) were associated with an increased risk of mortality (see Table 4). An additional consideration of the previous anti-tumour treatments within the multivariable models had no relevant impact on the results. Additional multivariate analyses were conducted in the total study population after adjusting for age, body mass index (BMI) and tumour stage, which presented comparable results (data not shown). There was a strong correlation between IL-4 and IL-1β (r = 0·650, P < 0·001) and between IL-1β and IL-6 (r = 0·537, P < 0·001), respectively. 256
In the subgroups, which were made depending on the tumour type, no significance was found between either IL levels and survival in breast cancer, or prostate cancer or brain tumours, whereas in patients with colon carcinoma higher IL-6 levels correlated significantly with decreased survival (HR per double increase = 2·27, 95% CI = 1·227– 4·371, P = 0·009); see Table 5a. Patients with lung cancer showed a significant association of elevated IL-10 levels with a decrease in survival (HR per double increase = 1·82, 95% CI = 1·097–2·927, P = 0·021); see Table 5b. The Kaplan–Meier curves (see Fig. 1) illustrate the survival rates in our cancer patients according to the IL-6, IL-8, Table 4. Interleukin (IL) levels and survival in patients with solid tumours: multivariable Cox regression analyses, including cytokine levels, age, gender and tumour stage. Parameter
HR
Age* Gender† M-stage‡ IL-1β§ IL-3§ IL-4§ IL-6§ IL-8§ IL-10§ IL-11§ CCL-3§
1·01 0·89 4·63 0·92 0·97 0·96 1·17 1·10 1·05 0·98 0·96
95% CI
P-value
0·994 0·692 3·435 0·813 0·884 0·818 1·101 1·030 0·918 0·894 0·911
1·017 1·141 6·237 1·039 1·062 1·129 1·251 1·173 1·204 1·068 1·010
0·338 0·353 < 0·001 0·0245 0·710 0·1445 < 0·0015 0·0145 0·1285 0·6325 0·0885
5 P-value for the combination of the binary and continuous variable. *Per year of life; †female versus male; ‡distant versus no distant metastasis; §hazard ratio (HR) per double increase of the continuous IL serum levels. CI = confidence interval; CCL-3 = chemokine ligand 3.
Table 5. Tumour types – subanalysis (multivariable Cox regression analyses). (a) Colorectal cancer Survival Parameter
HR
Age* Gender† M-stage‡ IL-64
1·02 1·22 6·00 2·27
95% CI 0·990 0·635 2·613 1·227
P-value 1·045 2·267 16·783 4·371
0·216 0·547 < 0·001 0·0095
(b) Lung cancer Survival Parameter
HR
Age* Gender† M-stage‡ IL-10§
1·02 0·66 2·53 1·82
95% CI 0·997 0·425 1·416 1·097
P-value 1·047 1·009 4·911 2·927
0·084 0·055 0·001 0·0215
5
P-value for the combination of binary and continuous variables. *Per year of life; †female versus male; ‡distant versus no distant metastasis; §hazard ratio (HR) per double increase of the continuous interleukin (IL) serum levels. CI = confidence interval.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
ILs – predictors for survival in cancer (a)
(b)
1·00
1·00
0·75
0·75
0·50
0·50
0·25
0·25 0·00
0·00 0 100 200 300 400 500 600 700 800 Days IL–8
below DL
above DL
IL–11
(c)
(d)
1·00
1·00
0·75
0·75
0·50
0·50
0·25
0·25
below DL
above DL
0·00
0·00 Fig. 1. Kaplan–Meier curves discriminating between patients with interleukin (IL) serum levels equal to or greater than zero. (a) Probability of survival in patients with IL-8 levels below and above detection limit (DL) (log-rank: P = 0·030). (b) Probability of survival in patients with IL-11 levels below and above DL (log-rank: P = 0·004). (c) Probability of survival in patients with IL-6 levels below and above DL (log-rank: P < 0·001). (d) Probability of survival in colorectal cancer patients with IL-6 levels below and above DL (log-rank: P = 0·004). (e) Probability of survival in patients with IL-10 levels below and above DL (log-rank: P = 0·160). (f) Probability of survival in lung cancer patients with IL-10 levels below and above DL (log-rank: P = 0·130); x-axis: survival time in days; y-axis: survival distribution function.
0 100 200 300 400 500 600 700 800 Days
0 100 200 300 400 500 600 700 800
0 100 200 300 400 500 600 700 800
Days
Days
IL–6
below DL
IL–6
above DL
(e) 1·00
(f) 1·00
0·75
0·75
0·50
0·50
0·25
0·25
0·00
below DL
above DL
0·00 0 100 200 300 400 500 600 700 800 Days IL–10
IL-10 and IL-11 levels, discriminating between patients with IL serum levels equal to zero or greater than zero, respectively.
Discussion In the present prospective cohort study, we investigated the association between levels of IL/CCL-3 and the occurrence of VTE in cancer patients. While we did not observe a significant correlation between cytokine levels and the occurrence of VTE in the total study population, we found a
below DL
above DL
0 100 200 300 400 500 600 700 800 Days IL–10
below DL
above DL
correlation between levels of IL-1β and IL-6 and VTE in pancreatic cancer patients. However, these data are hampered by the very low patient number (only 47 pancreatic cancer patients). In order to evaluate this thoroughly, further studies with higher patient numbers would be of interest. Regarding mortality, a correlation between IL-6, IL-8 and IL-11 and mortality was observed. We were able to define elevated levels of IL-6 and IL-10 as risk factors for increased mortality in patients with colorectal cancer and patients with lung cancer, respectively.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
257
E.-M. Reitter et al.
Associations of cytokine levels and VTE have not been studied previously in cancer patients, with the exception of IL-6. A recent study conducted by Malaponte et al. [32] found that IL-6 plasma levels were higher in cancer patients with a DVT compared to cancer patients without DVT as well as healthy individuals. Further, two case–control studies with discrepant results have been reported for noncancer patients. In patients without cancer, Christiansen et al. [33] found no correlation between elevated levels of IL-6, IL-8, IL-10 and IL-1β and incidence of venous thromboembolic events. Van Aken et al. [34] reported that increased IL-8 levels (>90th percentile) were associated with a 1·9-fold increased risk for thrombosis. In patients with recurrent venous thrombosis, van Aken et al. also found an association between increased levels of IL-6 and IL-8 and the recurrence of venous thrombosis. Regarding the prognostic quality of the investigated cytokines, the underlying molecular mechanisms and the exact cellular sources of these immunomodulatory signal molecules are currently widely unknown and warrant further investigation. Enhanced levels of the multi-functional, proinflammatory cytokine IL-6 might be derived from either infiltrating immune cells, stromal cells or the cancer cell itself [35,36]. The less-investigated IL-6 family member IL-11 can be produced by myeloid cells, but also by cancer-associated fibroblasts or cancer cells [37]. IL-6 is known to directly promote tumour growth, but also facilitates immune invasion by several signalling pathways, in particular the signal transducer and transcription activator 3 [36]. Moreover, IL-6 might not only be induced by chemotherapy, but also mediate therapy resistance, which could add to the worse prognosis of patients with high circulating IL-6 levels [38]. Interestingly, in a former study by our group, enhanced levels of C-reactive protein (CRP), an acute-phase protein known to be induced strongly by IL-6, indicated a worse prognosis of cancer patients not associated with VTE frequency [13]. These observations suggest that a direct tumour-promoting effect might underlie the negative prognostic impact of IL-6. Accordingly, another proinflammatory cytokine connected to worse prognosis is the CXC chemokine IL-8, frequently produced by cancer cells. Interestingly, both IL-6 and IL-8 are stimulated by macrophage migration inhibitory factor 1 (MIF) expressed by multiple immune cells in the cancer tissues, sustaining macrophage survival [39]. These observations support the hypothesis that the persistence of a proinflammatory tumour environment also drives disease progression within the investigated mixed patient cohort. However, in lung cancer, the usually immunosuppressive cytokines such as IL-10, acting primarily on macrophages and dentritic cells [40], also correlate with a worse prognosis. This indicates that the prognostic quality of these cytokines might generally reflect the consequences of the immunoediting process and the avoidance of immune destruction known as one of the hallmarks of cancer [41]. As our CATS cohort includes patients with 258
diverse cancer types, these data support the recently developed concept that such cytokine patterns are potentially a manifestation of an underlying systemic ‘paraneoplastic’ immune response that seems to be a consistent characteristic of patients suffering from diverse forms of cancer [42]. Previous studies have already shown that elevated levels of IL-6 correlated with lower survival rates [30,43] of cancer patients, including those of metastatic breast cancer [44], gastrointestinal cancer [28], metastatic renal cell carcinoma [29] prostate cancer [45] and lung cancer [46,47]. IL-8 levels were reported to be higher in patients with non-small-cell lung cancer than in healthy controls. Elevated levels correlated with shorter overall survival, but were not shown to be an independent prognostic factor [20]. In another study in previously untreated patients with non-small-cell lung cancer, IL-10 levels were elevated compared to healthy controls. IL-10 levels were decreased in patients who responded to chemotherapy, but were not affected in those with disease progression. Patients with IL-10 levels >19·6 pg/ml showed increased mortality compared to those with values ≤19·6 pg/ml [48]. Thus, these findings are consistent with those of our study. Moreover, Kaminska et al. showed that a rise of IL-6 and IL-10 concentrations in lung cancer patients was related significantly to the tumour size. In addition, patients with squamous cell carcinoma of the lung had higher circulating IL-6 levels compared to patients with adenocarcinomas. With regard to survival, Kaminska et al. did not find an association between the above-mentioned IL levels and survival [47]. It has already been reported by Baune et al. that an increase of IL-6 levels is related to higher mortality [49], which resembles our results. A strength of our study is that we included a large number of patients with various tumour entities and investigated seven different ILs. One limitation of our study is that we observed only 52 patients with VTE in our study population, despite the large number of patients with many different tumour entities enrolled into our study. IL levels were determined only at the time of inclusion prior to any anti-cancer therapy. However, a longitudinal determination of IL levels during the cytostatic treatment would be of further interest. In conclusion, we did not find an association between different IL-levels and the occurrence of VTE, with the exception of a trend for IL-1β and IL-6 in pancreatic cancer patients. Our results indicate that IL-6, IL-8 and IL-11 are associated with increased mortality in cancer patients. IL-6 and IL-10 are associated with patients’ prognosis in colorectal and lung cancer, respectively. In the future, more extensive studies are needed in order to evaluate the role of these ILs as relevant biomarkers in cancer patients regarding their survival.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
ILs – predictors for survival in cancer
Acknowledgements We would like to thank University Professor Dr Walter Berger (Institute of Cancer Research) for his input regarding tumour immunology. The CATS project was supported by a grant from the Jubilaeumsfonds of the Austrian National Bank (project numbers 10935 and 12739).
Disclosures All authors state that they have no conflicts of interest.
Author contributions C. A., I. P., E.-M. R. carried out the study concept and design. C. A., A. K., I. P., E.-M. R. analysed and interpreted the data. C. A., I. P., E-M. R. drafted the manuscript. C. A., A. K., I. P., R. P., E.-M. R., C. Z., G. Z. critically revised the manuscript for important intellectual content. A. K. conducted the statistical analysis. I. P. was the study supervisor.
References 1 Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. Am J Roentgenol 2007; 189:162–70. 2 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5:632–4. 3 Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490–505. 4 Gao S, Escalante C. Venous thromboembolism and malignancy. Exp Rev Anticancer Ther 2004; 4:303–20. 5 Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur J Surg Oncol 2011; 37:1072–7. 6 Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117:1334–49. 7 Martin LK, Bekaii-Saab T. Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? Thrombosis 2012; 2012:758385. 8 Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost 2010; 8:1702–9. 9 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLOS Med 2012; 9:e1001275. 10 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ, III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med 2000; 160:809–15.
11 Sousou T, Khorana A. Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie 2009; 29:121–4. 12 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715–22. 13 Kanz R, Vukovich T, Vormittag R et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011; 9:57–63. 14 Vormittag R, Simanek R, Ay C et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29:2176–81. 15 Ay C, Simanek R, Vormittag R et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703–8. 16 Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res 2012; 129 (Suppl. 1):S6–S9. 17 Noble S, Pasi J. Epidemiology and pathophysiology of cancerassociated thrombosis. Br J Cancer 2010; 102 (Suppl. 1):S2–S9. 18 Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004; 2:2107–14. 19 Vormittag R, Hsieh K, Kaider A et al. Interleukin-6 and interleukin-6 promoter polymorphism (-174) G > C in patients with spontaneous venous thromboembolism. Thromb Haemost 2006; 95:802–6. 20 Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 2013; 39:89–96. 21 Orditura M, De VF, Catalano G et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002; 22:1129–35. 22 Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska A, Fuksiewicz M. CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000; 6:38–41. 23 Wang YC, Sung WW, Wu TC et al. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLOS ONE 2012; 7:e39525. 24 Yanagawa H, Sone S, Takahashi Y et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71:1095–8. 25 Heikkila K, Harris R, Lowe G et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009; 20:15–26. 26 Songur N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, Hizel N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004; 90:196–200. 27 De VF, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5:649– 52. 28 De VF, Romano C, Orditura M et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
259
E.-M. Reitter et al.
29
30
31
32
33
34
35 36
37
38
260
patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21:45–52. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997; 33:1794–8. Chang CH, Hsiao CF, Yeh YM et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced non-small cell lung cancer patients treated with chemotherapy. Int J Cancer 2013; 132:1977–85. Guan E, Wang J, Norcross MA. Identification of human macrophage inflammatory proteins 1alpha and 1beta as a native secreted heterodimer. J Biol Chem 2001; 276:12404–9. Malaponte G, Polesel J, Candido S et al. IL-6–174 G > C and MMP-9-1562 C > T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine 2013; 62:64–9. Christiansen SC, Naess IA, Cannegieter SC, Hammerstrom J, Rosendaal FR, Reitsma PH. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLOS Med 2006; 3:e334. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116:173–7. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007; 117:3660–3. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904–10. Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 2010; 88:1109–17. Chang CH, Hsiao CF, Yeh YM et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung
39 40 41 42 43
44
45
46
47
48
49
cancer patients treated with chemotherapy. Int J Cancer 2013; 132:1977–85. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3:791–800. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008; 226:205–18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646–74. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14:e218–e228. Galizia G, Orditura M, Romano C et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002; 102:169–78. Salgado R, Junius S, Benoy I et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103:642–6. Nakashima J, Tachibana M, Horiguchi Y et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6:2702–6. Martin F, Santolaria F, Batista N et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80–6. Kaminska J, Kowalska M, Kotowicz B et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with nonsmall cell lung cancer, and correlations with clinicopathological features and prognosis. Oncology 2006; 70:115–25. De VF, Orditura M, Galizia G et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000; 117:365–73. Baune BT, Rothermundt M, Ladwig KH, Meisinger C, Berger K. Systemic inflammation (interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study. Age (Dordr) 2011; 33:209–17.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
Clinical and Experimental Immunology
O R I G I N A L A RT I C L E
doi:10.1111/cei.12308
Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients
E.-M. Reitter,* C. Ay,* A. Kaider,† R. Pirker,‡ C. Zielinski,‡ G. Zlabinger§ and I. Pabinger* *Clinical Division of Hematology and Hemostaseology, §Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center, †Section for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, and ‡Center of Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria
Accepted for publication 24 February 2014 Correspondence: I. Pabinger, Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria. E-mail: [email protected]
Summary Cytokines have been found to be elevated in cancer patients and have been associated with worse prognosis in single tumour entities. We investigated the association of eight different cytokines with venous thromboembolism (VTE) and prognosis in cancer patients. The Vienna Cancer and Thrombosis Study (CATS), a prospective study, includes patients with newly diagnosed tumour or disease progression. Patients with an overt infection are excluded. Study end-points are VTE, death, loss to follow-up or study completion. Interleukin (IL) serum levels were measured using the xMAP technology developed by Luminex. Among 726 included patients, no associations between IL levels and VTE were found, with the exception of a trend for IL-1β and IL-6 in pancreatic cancer. Elevated levels of IL-6 [as continuous variable per double increase hazard ratio (HR) = 1·07, 95% confidence interval (CI) = 1·027–1·114, P = 0·001, IL-8 (HR = 1·12, 95% CI = 1·062–1·170, P < 0·001) and IL-11 (HR = 1·37, 95% CI = 1·103–1·709, P = 0·005] were associated with worse survival. In subgroup analyses based on tumour type, colon carcinoma patients, who had higher IL-6 levels, showed a shorter survival (HR = 2·405, 95% CI = 1·252–4·618, P = 0·008). A significant association of elevated IL-10 levels with a decrease in survival (HR = 1·824, 95% CI = 1·098–3·031, P = 0·020) was seen among patients with lung cancer. No correlation between VTE and IL levels was found, but higher IL-6, IL-8 and IL-11 levels were associated with worse survival in cancer patients. Further, elevated IL-6 levels might be a prognostic marker in colorectal cancer and elevated IL-10 levels in lung cancer patients. Keywords: cancer, interleukin levels, survival, thrombosis
Introduction Cancer is associated with the occurrence of venous thromboembolism (VTE) [1], which affects up to 20% of all cancer patients [2–4]. However, the rate may even be underestimated because of asymptomatic VTE. The incidence of VTE differs widely between the various tumour types [1,5,6], with the highest risk of VTE observed in patients suffering from pancreatic, stomach, lung or colorectal cancer, as well as in patients with brain tumours [6–9]. The occurrence of VTE negatively affects the prognosis of cancer patients and is among the most important causes of death in these patients [10–12]. Many risk factors related to patient characteristics, tumour types and treatment influence the development of VTE in cancer patients [6]. A
number of biomarkers of haemostasis and inflammatory markers have been found to play the role of risk factors of VTE in patients with cancer [13–16]. There is evidence that elevated levels of interleukins (ILs) could be associated with VTE [17–19]. Various ILs are elevated in cancer patients, dependent upon type and stage of the tumours [20,21]. In particular, IL-6 and IL-8 play an important role in the process of inflammation and, therefore, also in the development and progression of cancer. IL-6 induces both T-lymphocyte proliferation and angiogenesis, which then influence growth, differentiation and migration of tumour cells. IL-8 is involved in stimulating neutrophils and angiogenesis [22]. IL-10, which acts as an immunoinhibitory cytokine, is often elevated in patients with lung cancer, whereas in patients with colorectal cancer
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
253
E.-M. Reitter et al.
the levels of IL-6 are increased [19,21,23–25]. Elevated levels of circulating IL-6 and IL-8 are often associated with poor survival rates, especially in patients suffering from lung cancer [24,26–30]. The macrophage inflammatory protein-1α [CCL-3 (chemokine ligand 3)] is involved in acute inflammation via recruiting and activating leucocytes [31]. In the present study, we evaluated the associations between different ILs and the occurrence of VTE as well as overall survival in patients with cancer.
Materials and methods Patients
day of study entry. All blood samples were collected at the same time of day, in the morning (9 a.m.–12 p.m.). The serum blood was then centrifuged at 3600 g for 10 min using the Rotanta/TRC centrifuge (Hettich, Tuttlingen, Germany). Serum aliquots were stored at −80°C until measurements were conducted in series. The samples of each individual patient were coded prior to laboratory analysis. Assessment of cytokine serum levels was performed using the xMAP technology developed by Luminex (Riverside, CA, USA). This is a bead-based system for multiplex testing of cytokines, chemokines and growth factors. Specific anticytokine antibodies as well as recombinant cytokines were obtained from R&D Systems (Minneapolis, MN, USA). Measurements were performed using a Luminex analyser.
Statistical analysis
This study included patients with cancer who were recruited into the Vienna Cancer and Thrombosis Study (CATS), an ongoing prospective and observational cohort study initiated in October 2003. The details of the study have been described previously [15,19]. The study was approved by the ethics committee of the Medical University of Vienna. Each patient gave his/her written informed consent. CATS enrolled patients with cancer of the breast, lung, upper or lower gastrointestinal tract, pancreas, kidney, prostate or other sites and patients with haematological malignancies. Patients were divided into newly diagnosed cancer patients versus those with disease progression after complete or partial remission, and were observed for a period of up to 2 years. Patients with an overt bacterial or viral infection within the last 2 weeks or who had undergone surgery or radiotherapy within the last 2 weeks, as well as patients who had had chemotherapy or a venous or arterial thromboembolism within the last 3 months, were excluded from study entry. Patients treated with vitamin K antagonists or low-molecular-weight heparin (LMWH) for long-term anti-coagulation were also excluded. However, thromboprophylaxis while being hospitalized was not an exclusion criterion. At the time of inclusion, data on medical history, type and stage of tumour were collected. During the observation period, patients were contacted by postal mail or telephone approximately every 3 months in order to collect data on the clinical course of their disease, in particular concerning the occurrence of VTE and anticancer treatment. Study end-points were the occurrence of VTE (which had to be confirmed objectively by means of duplex sonography, phlebography, computerized tomography or ventilation– perfusion lung scan), death due to any cause, loss to follow-up or completion of the 2-year study period.
Continuous variables are described by the mean ± standard deviation or the median and the 25th–75th percentiles in case of non-normally distributed continuous data. Categorical variables are described by absolute numbers and percentages. The median follow-up time was calculated using the reverse Kaplan–Meier method. Survival probabilities were estimated by the Kaplan–Meier method. Spearman’s correlation coefficient was used to describe the degree of correlation between the investigated IL serum levels. Univariate and multivariable Cox regression analyses were used to evaluate the effect of the IL serum levels on the development of VTE and on survival. With respect to the outcome of VTE, the observation end-point was fatal or non-fatal VTE. Data were censored at death, end of observation period after 2 years or loss to follow-up. Considering the end-point death, data were censored at the end of the observational period after 2 years or loss to follow-up. Due to the large number of patients with IL serum levels equal to zero, each of the investigated IL parameters was represented by two prognostic factors within the Cox regression models: first, a binary variable discriminating between patients with IL serum levels equal to zero or greater than zero, and secondly a continuous variable comprising the log2-transformed IL serum level of patients with IL serum levels greater than zero. The log2-transformation was used to normalize the skewed distribution of IL serum levels greater than zero. The value of the continuous variable was set to zero in the case of patients with zero IL serum levels. Two-sided P-values smaller than 0·05 were considered to indicate statistical significance. All analyses were performed with sas version 9·3.
Laboratory analysis
Study population
Venous blood samples were drawn by atraumatic and sterile vein puncture into vacuum tubes with serum clot activator (Vacuette, Greiner-Bio One, Kremsmuenster, Austria) on the
Overall, 726 cancer patients with a median age of 62·0 years were included between October 2003 and March 2009. Patient characteristics are listed in Table 1.
254
Results
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
ILs – predictors for survival in cancer Table 1. Patient characteristics (n = 726).
Outcome VTE
Age at study entry, median (min.; max.), years BMI, mean ± s.d., kg/m2 Gender Male Female Type of cancer Brain Breast Colon Kidney Lung Lymphoma Multiple myeloma Pancreas Prostate Stomach Others Treatment before study inclusion (ie. CHT, RT or surgery)
62·0 (18; 88) 25·3 ± 4·5 n (%) 382 (52·6) 344 (47·4) n (%) 77 (10·6) 129 (17·8) 98 (13·5) 22 (3·0) 109 (15·0) 70 (9·6) 15 (2·1) 47 (6·5) 75 (10·3) 37 (5·1) 47 (6·5) 311 (42·8)
BMI = body mass index; CHT = chemotherapy; RT = radiotherapy; s.d. = standard deviation.
The tumour types consist of malignancies of the breast (n = 129), brain (n = 77), lung (n = 109), stomach (n = 37), colon (n = 98), pancreas (n = 47), kidney (n = 22), prostate (n = 75), multiple myeloma (n = 15) and lymphoma (n = 70). Other tumour entities, such as malignancies of the gynaecological system, sarcoma, cholangiocellular carcinoma and urothelial carcinoma, are combined in the ‘others’ group (n = 47). Among solid tumours, localized tumours were found in 263 patients, whereas distant metastasis was present in 301 patients. There were 539 newly diagnosed patients, and 187 patients had suffered from disease progression following a complete or partial remission. The median follow-up time of the patients was 705 days (25th–75th percentiles: 262– 731 days).
During the study period, 52 patients (7·2%) developed a VTE. Of these patients, 25 (48·1%) had a deep vein thrombosis (DVT), 19 (36·5%) a pulmonary embolism (PE), one of which had a fatal PE, two a combined DVT and PE (3·8%) and six (11·5%) other kinds of VTE (portal vein thrombosis, sinus vein thrombosis, brachial vein thrombosis, inferior vena cava thrombosis, jugular vein thrombosis). In the total study population, none of the investigated cytokine levels (i.e. IL-1β, IL-3, IL-4, IL-6, IL-8, IL-10, IL-11, CCL-3) showed an association with the occurrence of VTE (see Table 2). Separate analyses were performed regarding the different tumour entities. In these analyses, only tumour entities with a VTE rate of more than 5% (i.e. cancer of the brain, colon, lung, pancreas and stomach) were considered. Evaluating the effects of the binary prognostic factors (levels below versus levels above detection limit) only in patients with pancreatic cancer, IL-1β [hazard ratio (HR) = 7·16, 95% confidence interval (CI) = 1·906–30·895, P = 0·004) and IL-6 (H = 13·23, 95% CI = 1·656–1711·29, P = 0·01] were associated with an increased risk for VTE.
Outcome survival Overall, 337 patients (46·4%) died within the study period. In univariate analyses, no correlation was found between the levels of IL-1β, IL-3, IL-4, IL-10 and CCL-3 and survival (see Table 2). Both a twofold increase of IL-6 levels (HR per double increase = 1·07, 95% CI = 1·027–1·114, P = 0·001) and IL-8 levels (HR per double increase: 1·12, 95% CI = 1·062–1·170, P < 0·001) were associated with poor survival. IL-11 levels above zero also correlated negatively with the patients’ survival (HR per double increase = 1·37, 95% CI = 1·103– 1·709, P = 0·005). However, among the group of patients
Table 2. Cytokine levels in univariate Cox regression analyses in the study population. VTE Parameter
HR
Age* Gender† M-stage‡ IL-1β§ IL-3§ IL-4§ IL-6§ IL-8§ IL-10§ IL-11§ CCL-3§
0·99 0·86 2·50 0·98 0·99 1·11 1·08 1·06 1·01 0·90 0·99
Survival
95% CI 0·97 0·50 1·22 0·80 0·84 0·86 0·98 0·94 0·83 0·76 0·90
1·01 1·49 5·09 1·20 1·18 1·42 1·20 1·20 1·22 1·06 1·10
P-value
HR
0·323 0·587 0·012 0·792 0·549 0·708 0·118 0·210 0·302 0·349 0·726
1·01 0·78 5·09 1·02 1·03 0·10 1·07 1·12 1·05 0·97 0·98
95% CI 1·00 0·63 3·81 0·94 0·96 0·90 1·03 1·06 0·97 0·91 0·94
P-value 1·02 0·97 6·80 1·11 1·10 1·11 1·11 1·17 1·14 1·04 1·02
0·004 0·027 < 0·001 0·5885 0·4495 0·9765 < 0·0015 < 0·0015 0·1585 0·0115 0·6045
P-value for the combination of the binary and continuous variable. *Per year of life; †female versus male; ‡for solid tumours only; §hazard ratio (HR) per double increase of the continuous interleukin (IL) serum levels. CCL-3 = chemokine ligand 3; VTE = venous thromboembolism; CI = confidence interval. 5
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
255
E.-M. Reitter et al. Table 3. Interleukin (IL) levels and survival in the study population: multivariable Cox regression analyses, including cytokine levels, age and gender-adjusted. Parameter
HR
Age* Gender† IL-1β‡ IL-3‡ IL-4‡ IL-6‡ IL-8‡ IL-10‡ IL-11‡ CCL-3‡
1·01 0·85 0·93 0·95 0·95 1·15 1·12 1·07 0·94 0·93
95% CI 0·997 0·680 0·838 0·879 0·825 1·089 1·051 0·952 0·865 0·890
P-value 1·015 1·061 1·040 1·032 1·089 1·211 1·182 1·194 1·014 0·977
0·210 0·151 0·0204 0·4704 0·6924 < 0·0014 < 0·0014 0·5214 0·0124 0·0044
4
P-value for the combination of the binary and continuous variable. *Per year of life; †female versus male; ‡hazard ratio (HR) per double increase of the continuous IL serum levels. CI = confidence interval; CCL-3 = chemokine ligand 3.
with IL-11 levels above zero, the extent of the IL-11 level seemed to have no further influence on survival (HR per double increase = 0·97, 95% CI = 0·908–1·037, P = 0·376). In multivariable analyses, after adjustment for age and gender, the association of the levels of IL-1β (HR per double increase = 0·93, 95% CI = 0·838–1·040, P = 0·020), IL-6 (HR per double increase = 1·15, 95% CI, 1·089–1·211, P < 0·001), IL-8 (HR per double increase = 1·12, 95% CI = 1·051 −1·182, P < 0·001) and IL-11 (HR per double increase = 0·94, 95% CI = 0·865–1·014, P = 0·012) with risk of mortality remained statistically significant. Patients with increased CCL-3 levels showed a better survival outcome (HR per double increase = 0·93, 95% CI = 0·89–0·977, P = 0·004). For detailed results see Table 3. Furthermore, we performed multivariable analyses with adjustment for age, gender and tumour stage (localized tumour versus distant metastasis) by including only the solid tumours. For these analyses, we excluded patients with brain tumours as well as patients with multiple myeloma and lymphoma. From the remaining patients (n = 564), 276 (48·9%) died within the follow-up period (55% male). In these patients, IL-6 (HR per double increase = 1·173, 95% CI = 1·100–1·251, P < 0·001) and IL-8 (HR per double increase = 1·092, 95% CI = 1·023–1·166, P = 0·008) were associated with an increased risk of mortality (see Table 4). An additional consideration of the previous anti-tumour treatments within the multivariable models had no relevant impact on the results. Additional multivariate analyses were conducted in the total study population after adjusting for age, body mass index (BMI) and tumour stage, which presented comparable results (data not shown). There was a strong correlation between IL-4 and IL-1β (r = 0·650, P < 0·001) and between IL-1β and IL-6 (r = 0·537, P < 0·001), respectively. 256
In the subgroups, which were made depending on the tumour type, no significance was found between either IL levels and survival in breast cancer, or prostate cancer or brain tumours, whereas in patients with colon carcinoma higher IL-6 levels correlated significantly with decreased survival (HR per double increase = 2·27, 95% CI = 1·227– 4·371, P = 0·009); see Table 5a. Patients with lung cancer showed a significant association of elevated IL-10 levels with a decrease in survival (HR per double increase = 1·82, 95% CI = 1·097–2·927, P = 0·021); see Table 5b. The Kaplan–Meier curves (see Fig. 1) illustrate the survival rates in our cancer patients according to the IL-6, IL-8, Table 4. Interleukin (IL) levels and survival in patients with solid tumours: multivariable Cox regression analyses, including cytokine levels, age, gender and tumour stage. Parameter
HR
Age* Gender† M-stage‡ IL-1β§ IL-3§ IL-4§ IL-6§ IL-8§ IL-10§ IL-11§ CCL-3§
1·01 0·89 4·63 0·92 0·97 0·96 1·17 1·10 1·05 0·98 0·96
95% CI
P-value
0·994 0·692 3·435 0·813 0·884 0·818 1·101 1·030 0·918 0·894 0·911
1·017 1·141 6·237 1·039 1·062 1·129 1·251 1·173 1·204 1·068 1·010
0·338 0·353 < 0·001 0·0245 0·710 0·1445 < 0·0015 0·0145 0·1285 0·6325 0·0885
5 P-value for the combination of the binary and continuous variable. *Per year of life; †female versus male; ‡distant versus no distant metastasis; §hazard ratio (HR) per double increase of the continuous IL serum levels. CI = confidence interval; CCL-3 = chemokine ligand 3.
Table 5. Tumour types – subanalysis (multivariable Cox regression analyses). (a) Colorectal cancer Survival Parameter
HR
Age* Gender† M-stage‡ IL-64
1·02 1·22 6·00 2·27
95% CI 0·990 0·635 2·613 1·227
P-value 1·045 2·267 16·783 4·371
0·216 0·547 < 0·001 0·0095
(b) Lung cancer Survival Parameter
HR
Age* Gender† M-stage‡ IL-10§
1·02 0·66 2·53 1·82
95% CI 0·997 0·425 1·416 1·097
P-value 1·047 1·009 4·911 2·927
0·084 0·055 0·001 0·0215
5
P-value for the combination of binary and continuous variables. *Per year of life; †female versus male; ‡distant versus no distant metastasis; §hazard ratio (HR) per double increase of the continuous interleukin (IL) serum levels. CI = confidence interval.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
ILs – predictors for survival in cancer (a)
(b)
1·00
1·00
0·75
0·75
0·50
0·50
0·25
0·25 0·00
0·00 0 100 200 300 400 500 600 700 800 Days IL–8
below DL
above DL
IL–11
(c)
(d)
1·00
1·00
0·75
0·75
0·50
0·50
0·25
0·25
below DL
above DL
0·00
0·00 Fig. 1. Kaplan–Meier curves discriminating between patients with interleukin (IL) serum levels equal to or greater than zero. (a) Probability of survival in patients with IL-8 levels below and above detection limit (DL) (log-rank: P = 0·030). (b) Probability of survival in patients with IL-11 levels below and above DL (log-rank: P = 0·004). (c) Probability of survival in patients with IL-6 levels below and above DL (log-rank: P < 0·001). (d) Probability of survival in colorectal cancer patients with IL-6 levels below and above DL (log-rank: P = 0·004). (e) Probability of survival in patients with IL-10 levels below and above DL (log-rank: P = 0·160). (f) Probability of survival in lung cancer patients with IL-10 levels below and above DL (log-rank: P = 0·130); x-axis: survival time in days; y-axis: survival distribution function.
0 100 200 300 400 500 600 700 800 Days
0 100 200 300 400 500 600 700 800
0 100 200 300 400 500 600 700 800
Days
Days
IL–6
below DL
IL–6
above DL
(e) 1·00
(f) 1·00
0·75
0·75
0·50
0·50
0·25
0·25
0·00
below DL
above DL
0·00 0 100 200 300 400 500 600 700 800 Days IL–10
IL-10 and IL-11 levels, discriminating between patients with IL serum levels equal to zero or greater than zero, respectively.
Discussion In the present prospective cohort study, we investigated the association between levels of IL/CCL-3 and the occurrence of VTE in cancer patients. While we did not observe a significant correlation between cytokine levels and the occurrence of VTE in the total study population, we found a
below DL
above DL
0 100 200 300 400 500 600 700 800 Days IL–10
below DL
above DL
correlation between levels of IL-1β and IL-6 and VTE in pancreatic cancer patients. However, these data are hampered by the very low patient number (only 47 pancreatic cancer patients). In order to evaluate this thoroughly, further studies with higher patient numbers would be of interest. Regarding mortality, a correlation between IL-6, IL-8 and IL-11 and mortality was observed. We were able to define elevated levels of IL-6 and IL-10 as risk factors for increased mortality in patients with colorectal cancer and patients with lung cancer, respectively.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
257
E.-M. Reitter et al.
Associations of cytokine levels and VTE have not been studied previously in cancer patients, with the exception of IL-6. A recent study conducted by Malaponte et al. [32] found that IL-6 plasma levels were higher in cancer patients with a DVT compared to cancer patients without DVT as well as healthy individuals. Further, two case–control studies with discrepant results have been reported for noncancer patients. In patients without cancer, Christiansen et al. [33] found no correlation between elevated levels of IL-6, IL-8, IL-10 and IL-1β and incidence of venous thromboembolic events. Van Aken et al. [34] reported that increased IL-8 levels (>90th percentile) were associated with a 1·9-fold increased risk for thrombosis. In patients with recurrent venous thrombosis, van Aken et al. also found an association between increased levels of IL-6 and IL-8 and the recurrence of venous thrombosis. Regarding the prognostic quality of the investigated cytokines, the underlying molecular mechanisms and the exact cellular sources of these immunomodulatory signal molecules are currently widely unknown and warrant further investigation. Enhanced levels of the multi-functional, proinflammatory cytokine IL-6 might be derived from either infiltrating immune cells, stromal cells or the cancer cell itself [35,36]. The less-investigated IL-6 family member IL-11 can be produced by myeloid cells, but also by cancer-associated fibroblasts or cancer cells [37]. IL-6 is known to directly promote tumour growth, but also facilitates immune invasion by several signalling pathways, in particular the signal transducer and transcription activator 3 [36]. Moreover, IL-6 might not only be induced by chemotherapy, but also mediate therapy resistance, which could add to the worse prognosis of patients with high circulating IL-6 levels [38]. Interestingly, in a former study by our group, enhanced levels of C-reactive protein (CRP), an acute-phase protein known to be induced strongly by IL-6, indicated a worse prognosis of cancer patients not associated with VTE frequency [13]. These observations suggest that a direct tumour-promoting effect might underlie the negative prognostic impact of IL-6. Accordingly, another proinflammatory cytokine connected to worse prognosis is the CXC chemokine IL-8, frequently produced by cancer cells. Interestingly, both IL-6 and IL-8 are stimulated by macrophage migration inhibitory factor 1 (MIF) expressed by multiple immune cells in the cancer tissues, sustaining macrophage survival [39]. These observations support the hypothesis that the persistence of a proinflammatory tumour environment also drives disease progression within the investigated mixed patient cohort. However, in lung cancer, the usually immunosuppressive cytokines such as IL-10, acting primarily on macrophages and dentritic cells [40], also correlate with a worse prognosis. This indicates that the prognostic quality of these cytokines might generally reflect the consequences of the immunoediting process and the avoidance of immune destruction known as one of the hallmarks of cancer [41]. As our CATS cohort includes patients with 258
diverse cancer types, these data support the recently developed concept that such cytokine patterns are potentially a manifestation of an underlying systemic ‘paraneoplastic’ immune response that seems to be a consistent characteristic of patients suffering from diverse forms of cancer [42]. Previous studies have already shown that elevated levels of IL-6 correlated with lower survival rates [30,43] of cancer patients, including those of metastatic breast cancer [44], gastrointestinal cancer [28], metastatic renal cell carcinoma [29] prostate cancer [45] and lung cancer [46,47]. IL-8 levels were reported to be higher in patients with non-small-cell lung cancer than in healthy controls. Elevated levels correlated with shorter overall survival, but were not shown to be an independent prognostic factor [20]. In another study in previously untreated patients with non-small-cell lung cancer, IL-10 levels were elevated compared to healthy controls. IL-10 levels were decreased in patients who responded to chemotherapy, but were not affected in those with disease progression. Patients with IL-10 levels >19·6 pg/ml showed increased mortality compared to those with values ≤19·6 pg/ml [48]. Thus, these findings are consistent with those of our study. Moreover, Kaminska et al. showed that a rise of IL-6 and IL-10 concentrations in lung cancer patients was related significantly to the tumour size. In addition, patients with squamous cell carcinoma of the lung had higher circulating IL-6 levels compared to patients with adenocarcinomas. With regard to survival, Kaminska et al. did not find an association between the above-mentioned IL levels and survival [47]. It has already been reported by Baune et al. that an increase of IL-6 levels is related to higher mortality [49], which resembles our results. A strength of our study is that we included a large number of patients with various tumour entities and investigated seven different ILs. One limitation of our study is that we observed only 52 patients with VTE in our study population, despite the large number of patients with many different tumour entities enrolled into our study. IL levels were determined only at the time of inclusion prior to any anti-cancer therapy. However, a longitudinal determination of IL levels during the cytostatic treatment would be of further interest. In conclusion, we did not find an association between different IL-levels and the occurrence of VTE, with the exception of a trend for IL-1β and IL-6 in pancreatic cancer patients. Our results indicate that IL-6, IL-8 and IL-11 are associated with increased mortality in cancer patients. IL-6 and IL-10 are associated with patients’ prognosis in colorectal and lung cancer, respectively. In the future, more extensive studies are needed in order to evaluate the role of these ILs as relevant biomarkers in cancer patients regarding their survival.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
ILs – predictors for survival in cancer
Acknowledgements We would like to thank University Professor Dr Walter Berger (Institute of Cancer Research) for his input regarding tumour immunology. The CATS project was supported by a grant from the Jubilaeumsfonds of the Austrian National Bank (project numbers 10935 and 12739).
Disclosures All authors state that they have no conflicts of interest.
Author contributions C. A., I. P., E.-M. R. carried out the study concept and design. C. A., A. K., I. P., E.-M. R. analysed and interpreted the data. C. A., I. P., E-M. R. drafted the manuscript. C. A., A. K., I. P., R. P., E.-M. R., C. Z., G. Z. critically revised the manuscript for important intellectual content. A. K. conducted the statistical analysis. I. P. was the study supervisor.
References 1 Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. Am J Roentgenol 2007; 189:162–70. 2 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5:632–4. 3 Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490–505. 4 Gao S, Escalante C. Venous thromboembolism and malignancy. Exp Rev Anticancer Ther 2004; 4:303–20. 5 Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur J Surg Oncol 2011; 37:1072–7. 6 Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117:1334–49. 7 Martin LK, Bekaii-Saab T. Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? Thrombosis 2012; 2012:758385. 8 Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost 2010; 8:1702–9. 9 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLOS Med 2012; 9:e1001275. 10 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ, III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med 2000; 160:809–15.
11 Sousou T, Khorana A. Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie 2009; 29:121–4. 12 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715–22. 13 Kanz R, Vukovich T, Vormittag R et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011; 9:57–63. 14 Vormittag R, Simanek R, Ay C et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29:2176–81. 15 Ay C, Simanek R, Vormittag R et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703–8. 16 Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res 2012; 129 (Suppl. 1):S6–S9. 17 Noble S, Pasi J. Epidemiology and pathophysiology of cancerassociated thrombosis. Br J Cancer 2010; 102 (Suppl. 1):S2–S9. 18 Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004; 2:2107–14. 19 Vormittag R, Hsieh K, Kaider A et al. Interleukin-6 and interleukin-6 promoter polymorphism (-174) G > C in patients with spontaneous venous thromboembolism. Thromb Haemost 2006; 95:802–6. 20 Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 2013; 39:89–96. 21 Orditura M, De VF, Catalano G et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002; 22:1129–35. 22 Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska A, Fuksiewicz M. CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000; 6:38–41. 23 Wang YC, Sung WW, Wu TC et al. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLOS ONE 2012; 7:e39525. 24 Yanagawa H, Sone S, Takahashi Y et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71:1095–8. 25 Heikkila K, Harris R, Lowe G et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009; 20:15–26. 26 Songur N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, Hizel N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004; 90:196–200. 27 De VF, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5:649– 52. 28 De VF, Romano C, Orditura M et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
259
E.-M. Reitter et al.
29
30
31
32
33
34
35 36
37
38
260
patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21:45–52. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997; 33:1794–8. Chang CH, Hsiao CF, Yeh YM et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced non-small cell lung cancer patients treated with chemotherapy. Int J Cancer 2013; 132:1977–85. Guan E, Wang J, Norcross MA. Identification of human macrophage inflammatory proteins 1alpha and 1beta as a native secreted heterodimer. J Biol Chem 2001; 276:12404–9. Malaponte G, Polesel J, Candido S et al. IL-6–174 G > C and MMP-9-1562 C > T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine 2013; 62:64–9. Christiansen SC, Naess IA, Cannegieter SC, Hammerstrom J, Rosendaal FR, Reitsma PH. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLOS Med 2006; 3:e334. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116:173–7. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007; 117:3660–3. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904–10. Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 2010; 88:1109–17. Chang CH, Hsiao CF, Yeh YM et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung
39 40 41 42 43
44
45
46
47
48
49
cancer patients treated with chemotherapy. Int J Cancer 2013; 132:1977–85. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3:791–800. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008; 226:205–18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646–74. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14:e218–e228. Galizia G, Orditura M, Romano C et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002; 102:169–78. Salgado R, Junius S, Benoy I et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103:642–6. Nakashima J, Tachibana M, Horiguchi Y et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6:2702–6. Martin F, Santolaria F, Batista N et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80–6. Kaminska J, Kowalska M, Kotowicz B et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with nonsmall cell lung cancer, and correlations with clinicopathological features and prognosis. Oncology 2006; 70:115–25. De VF, Orditura M, Galizia G et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000; 117:365–73. Baune BT, Rothermundt M, Ladwig KH, Meisinger C, Berger K. Systemic inflammation (interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study. Age (Dordr) 2011; 33:209–17.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 177: 253–260
